Executive Interview with Peter Sullivan, MyxoTech
Peter Sullivan
Chief Executive Officer
MyxoTech
Format: 17 minute interview
Related posts
Chemical Inducers of Proximity – Non-Degrading Molecular Glue Modalities
Unlocking the Promise of Protein Degraders: Molecular Glues, PROTACs, and the Path Forward
Designing Next-Gen Biomaterials: Peptide Hydrogels in 3D Culture & Regenerative Platforms
Unlocking the Brain- Innovations in CNS Drug Discovery and Neurodegenerative Treatment
Upcoming events
Drug Discovery US 2026
In-Person
Join top scientific experts at our annual Drug Discovery programme—where innovation meets impact. Dive into breakthrough strategies and cutting-edge advances in novel modalities, including PROTACs and molecular glues, and explore how AI and computational tools are reshaping early-stage discovery. Gain real-world insights from new case studies and stay ahead of the curve in accelerating the journey from target to candidate.
Formulation & Delivery US 2026
In-Person
Join world-leading experts in drug product development and delivery at Formulation & Delivery US, a must-attend in-person event in San Diego, the West Coast’s scientific hotspot. Discover cutting-edge advances in formulating large and small molecule drugs, breakthrough RNA developments, and game-changing innovations in delivering complex therapeutics.
